CJC-1295 clinical trials: what the human data actually shows

Last updated 2026-07-26

Is there an actual published clinical trial on CJC-1295?

Yes, one. The trial that anchors almost everything written about CJC-1295 is Teichman et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long acting growth hormone-releasing factor (GRF) analog," published in the Journal of Clinical Endocrinology & Metabolism in 2006 ^[1]. It enrolled 80 healthy adults and tested the DAC-conjugated form of the peptide (the version designed for sustained release) as single ascending doses and then as multiple doses over weeks. The topline finding, in the authors' own words: CJC-1295 "produced dose-dependent increases in GH and IGF-1 with mean increases of 2- to 10-fold in GH and up to 2- to 3-fold in IGF-1" and a single dose "increased plasma GH levels for 6 days and IGF-1 levels for 9 to 11 days" ^[1]. In the multi-dose arm, twice-weekly injections over multiple weeks kept mean IGF-1 levels elevated above baseline the entire time, without the sharp peaks and troughs you'd get from a short-acting GHRH. That is the entire dedicated human trial base. There is no second confirmatory phase 1 study, no phase 2 or phase 3 program, and no FDA-reviewed New Drug Application for CJC-1295 as a marketed drug. It was developed by a company called ConjuChem, which held patents and ran early trials, but the compound was never brought to market as an approved therapeutic ^[1][2]. Everything published after 2006 that discusses CJC-1295 in humans cites back to this same trial, directly or indirectly. That matters for how you read the rest of this article, and for how you should read anything else you find about CJC-1295 online. One well-conducted 2006 phase 1 trial tells you the peptide can raise GH and IGF-1 in a dose-dependent, sustained way over the trial's timeframe. It does not tell you what happens over 12 months, in people over 50, in people with metabolic disease, or when combined with other secretagogues.

What did the 2006 Teichman trial actually measure and find?

The design was a randomized, placebo-controlled, dose-escalation study. Subjects received single subcutaneous doses of DAC-CJC-1295 at several dose levels, and a separate cohort received repeated doses (roughly twice weekly) over an extended period, with GH and IGF-1 sampled repeatedly by blood draw ^[1]. Key numbers reported: after a single dose, mean GH levels stayed elevated for about 6 days, and IGF-1 stayed elevated for 9 to 11 days ^[1]. That long tail is the entire point of the DAC (Drug Affinity Complex) chemistry, discussed more in the next section. With repeated dosing, mean IGF-1 concentrations rose and were sustained above baseline through the multi-week dosing period, described by the authors as maintaining levels "within the normal physiological range" at the doses tested ^[1]. Safety reporting in the trial was limited to what a phase 1 pharmacokinetic study is built to catch: injection site reactions and short-term tolerability, over a period of weeks, not years. The paper does not report long-term cardiovascular, oncologic, or metabolic outcomes, because it wasn't designed or powered to. If you want the safety picture in more depth, including what's known and what's genuinely unknown, that's covered on the side effects page rather than here. One more honest caveat: 80 subjects is a workable phase 1 cohort size. It's small, though, by the standards of the multi-thousand-subject trials that support approved drugs. A single trial of this size, however well run, is not the same evidentiary weight as a replicated phase 3 program.

What's the difference between CJC-1295 with DAC and without DAC in the research?

This is the single most confused point in CJC-1295 discussion, and it matters for interpreting "the trial data" correctly. DAC stands for Drug Affinity Complex, a chemical modification that lets the peptide bind to circulating albumin after injection ^[1][2]. That albumin binding is what stretches the compound's effective half-life from minutes to days. The 2006 Teichman trial tested the DAC version specifically, and its multi-day GH and IGF-1 elevations are a direct consequence of that albumin-binding chemistry ^[1]. "CJC-1295 without DAC" is a different, shorter-acting molecule, more accurately described as modified GRF(1-29), essentially a stabilized fragment of growth hormone-releasing hormone with a half-life measured in minutes rather than days. It is not the compound the 2006 clinical trial tested. When you see it sold or discussed as "CJC-1295 no-DAC," understand that its supporting human evidence is not the Teichman trial; it rests instead on decades-old GHRH(1-29) and GRF(1-44) pharmacology research from the 1980s and 1990s, plus the general receptor biology of growth hormone-releasing hormone. That older GRF/GHRH literature is real and substantial (it underpins the approved drug sermorelin, itself a GHRH(1-29) analogue with an FDA-approved history, later discontinued commercially) ^[3]. But it's a different evidentiary chain from the CJC-1295 DAC trial, and conflating the two overstates what's known about the no-DAC version specifically. If you're trying to decide between formulations, the CJC-1295 with DAC page walks through the practical tradeoffs in more depth; the honest summary is that DAC has one real trial behind it and no-DAC largely borrows credibility from adjacent GHRH research. | Feature | CJC-1295 with DAC | CJC-1295 no-DAC (mod GRF 1-29) |

Has CJC-1295 been tested combined with ipamorelin?

No published clinical trial has tested the CJC-1295 plus ipamorelin combination specifically. This pairing is a compounding-pharmacy and research-community practice built on separate mechanistic logic, not a studied combination in a peer-reviewed trial. The rationale is real pharmacology, even if the combination itself is untested. CJC-1295 works through the GHRH receptor, telling the pituitary to synthesize and release more growth hormone. Ipamorelin works through the ghrelin receptor (GHS-R1a), the same pathway exploited by ghrelin-mimetic drugs, and it does so with notably more receptor selectivity than older GHRPs like GHRP-6. Ipamorelin's selectivity for GH release over cortisol, prolactin, and ACTH stimulation was characterized in earlier pharmacology work on ghrelin-receptor agonists, distinguishing it from first-generation GHRPs ^[4]. Combining a GHRH receptor agonist with a ghrelin receptor agonist to get a larger combined GH pulse than either alone is a well-established concept in endocrine pharmacology generally, because the two pathways act through different receptors on the same pituitary somatotroph cells. That two-pathway logic is legitimate physiology. What it is not is a clinical outcomes trial showing that CJC-1295 plus ipamorelin, in humans, over a defined period, produces a specific measured benefit (more lean mass, better sleep, lower body fat) beyond what either might do alone. Nobody has published that trial. If you see specific numeric claims about the combination's effects on body composition or sleep quality, those numbers are coming from forum reports or manufacturer marketing, not from a controlled study. For practical dosing approaches people use with the combination (again, protocol convention rather than trial protocol), see the CJC-1295 dosage page and the dosage calculator.

Is CJC-1295 FDA approved for any use?

No. CJC-1295 has no FDA approval for any indication, human or otherwise. It has never completed a phase 3 program and has no New Drug Application on file with the agency. The FDA's official position on compounded GH secretagogue peptides generally has been unfavorable for the class. Sermorelin, a related, once-approved GHRH(1-29) analogue, has its own more established regulatory history reflected in its archived FDA labeling ^[3]. CJC-1295 itself was never an approved drug and doesn't carry that history; it has no NDA, no approved label, and no FDA safety review on record. Practically, this means CJC-1295 sold in the US exists in a research-chemical or compounded-pharmacy gray zone, not as an FDA-approved prescription drug with an approved label and dosing instructions. Anyone telling you there's an "FDA-approved CJC-1295 protocol" is not describing a real regulatory status.

What does the trial say about how long GH and IGF-1 stay elevated?

The single-dose data from the 2006 trial is the most-cited number in the entire CJC-1295 literature, and it's worth stating precisely rather than loosely. Mean GH levels remained elevated for about 6 days after one dose of DAC-CJC-1295, and IGF-1 elevation persisted 9 to 11 days ^[1]. With the twice-weekly repeat-dosing schedule tested in the multi-dose arm, IGF-1 concentrations stayed elevated across the full multi-week observation window without returning to baseline between doses, which is the mechanistic basis for the twice-weekly dosing convention commonly discussed for DAC formulations ^[1]. This is fundamentally different pharmacokinetics from no-DAC CJC-1295 or from GHRH(1-29) itself, both of which clear in minutes and require much more frequent dosing to sustain any GH elevation, typically once or more daily, usually timed around sleep or fasting. One nuance often lost in secondary write-ups: the trial reported means across the dosed cohort, and dose-response was not flat. Higher doses produced larger and more sustained increases, and the paper describes the relationship as dose-dependent rather than an all-or-nothing switch ^[1]. That's a normal pharmacology finding. It means single anecdotal reports of "how long it lasted for me" from an unverified source are not equivalent to the trial's controlled, multi-dose-level data.

What long-term safety data exists from human trials?

Very little, and this is the honest gap in the evidence. The 2006 trial was a phase 1 pharmacokinetic and tolerability study over weeks, not a long-term safety trial over months or years. It was not designed to detect low-frequency adverse events, cancer risk signals, or effects on glucose metabolism over extended use, the kinds of outcomes that typically require phase 3 programs with hundreds to thousands of subjects followed for a year or more. What we do have is general endocrine knowledge about sustained GH/IGF-1 elevation from other contexts: acromegaly research (a disease state of chronic GH excess) documents associated risks including insulin resistance, cardiovascular changes, and joint or soft tissue effects when GH and IGF-1 are chronically elevated well above normal for years ^[5]. That's a different scenario (endogenous tumor-driven excess, not exogenous peptide dosing at physiologic-range targets), but it's the closest large body of long-term human data on what sustained elevated IGF-1 can do to a body over time, and it's a reasonable reason for caution rather than a direct prediction of what any specific CJC-1295 protocol will cause. No published trial has followed CJC-1295 users for a year or more and reported on cancer incidence, cardiovascular events, or diabetes onset. That's not a reassurance and it's not an alarm. It's simply an absence of data that anyone selling or writing about this compound should say plainly rather than filling in with confidence they don't have.

What claims about CJC-1295 come from bodybuilding forums rather than trials?

A lot of what circulates about CJC-1295 outside the 2006 trial is extrapolation, marketing copy, or forum-generalized anecdote, not data from a controlled study. It's worth naming the specific claims that fall into this category, because they get repeated as if they were trial findings. Claims not supported by the published trial: specific fat-loss percentages, specific muscle-gain timelines, sleep-quality scoring improvements, skin/collagen effects, injury-healing speed claims, and anti-aging framing generally. None of these outcomes were measured in the Teichman 2006 trial, which tracked GH and IGF-1 blood levels and basic tolerability, not body composition, skin biopsies, sleep architecture, or wound healing ^[1]. Any specific numeric claim about those outcomes you encounter is coming from somewhere other than the peer-reviewed trial base. Also in the folklore category: precise anecdotal dosing schedules presented as if they were clinically validated, claims that no-DAC and DAC versions are pharmacologically interchangeable, and claims that combining CJC-1295 with ipamorelin has been shown in trials to outperform either alone (addressed above, it hasn't been tested that way). None of this means these effects are impossible. It means they haven't been measured in a controlled trial, and forum consensus is not a substitute for one, however confidently it's stated. If you're trying to sort real pharmacology from repeated forum claims across the wider CJC-1295 literature, the main CJC-1295 evidence page is built to make that distinction across every major claim, more broadly than the trial-specific ones covered here.

Are there any newer trials since 2006, or ongoing research?

No large new dedicated CJC-1295 human trial has been published since the original 2006 Teichman study, as of this writing. Search of major trial registries and journal databases for CJC-1295-specific interventional studies in humans continues to return that same original trial as the primary source, cited repeatedly in later review articles and secondary literature rather than replaced by new primary data. There has been continued academic interest in GHRH analogues and ghrelin-receptor agonists as a drug class generally, including research into tesamorelin (an FDA-approved GHRH analogue for HIV-associated lipodystrophy, a genuinely different, approved use case with its own trial program) . Tesamorelin's approval and trial history is sometimes conflated with CJC-1295 because both are GHRH analogues, but they are distinct molecules with separate regulatory and trial histories; tesamorelin has FDA approval and a phase 3 program behind it, CJC-1295 does not . If a major new CJC-1295-specific human trial gets published, it would represent a genuine shift in the evidence base described in this article. As of now, the field is still working from one 2006 dataset.

How should you weigh this evidence if you're considering CJC-1295?

Weigh it as one solid but narrow phase 1 dataset, surrounded by a large amount of secondary extrapolation and product marketing that goes well beyond what that dataset showed. The 2006 trial is real, was peer-reviewed, and demonstrates that DAC-CJC-1295 does what it's mechanistically supposed to do: raise GH and IGF-1 in a dose-dependent, sustained way over a period of days to weeks ^[1]. That's a meaningful finding. It is not the same as a trial showing specific body composition outcomes, long-term safety over years, or superiority of any particular combination protocol. If you're weighing whether and how to use it, the honest sequence is: understand the actual trial data (this page), understand the DAC vs no-DAC pharmacokinetic distinction (above, and the CJC-1295 with DAC page), understand realistic dosing conventions derived from that pharmacokinetic profile (the dosage page and calculator), and understand the safety unknowns honestly (the side effects page) before you look at sourcing. Sourcing matters more than people think, given the regulatory gray zone described above. CJC-1295 Co reviews providers and points readers toward routes that involve provider oversight and pharmacy fulfillment rather than unverified direct-to-consumer vials; if you get to the point of actually sourcing the compound, the CJC-1295 for sale page covers what a provider-reviewed, pharmacy-fulfilled route looks like versus the unregulated alternative.

Frequently asked questions

How many clinical trials has CJC-1295 gone through?

Essentially one dedicated published human trial: Teichman et al. 2006 in the Journal of Clinical Endocrinology & Metabolism, an 80-subject phase 1 dose-escalation study of DAC-CJC-1295. No phase 2 or 3 program followed, and no FDA approval has ever been granted for the compound.

Did the CJC-1295 trial test the no-DAC version?

No. The 2006 trial tested the DAC (Drug Affinity Complex) form, which binds albumin for a multi-day effect. The shorter-acting no-DAC version, more accurately called modified GRF(1-29), was not the compound studied in that trial and has no dedicated published human trial of its own.

Is there clinical evidence for CJC-1295 combined with ipamorelin?

No. There's no published trial testing the combination directly. The rationale (GHRH receptor plus ghrelin receptor stimulation acting on different pathways) is sound pharmacology, but claimed combined effects on body composition or sleep are not demonstrated in a controlled human study.

Is CJC-1295 approved by the FDA?

No. CJC-1295 has never received FDA approval for any indication. It has no completed phase 3 trials, no New Drug Application on file, and no approved label. Only the related molecule sermorelin has an FDA-reviewed history, and that history does not transfer to CJC-1295.

How long does CJC-1295 raise GH and IGF-1 according to the trial?

In the 2006 single-dose data, mean GH stayed elevated about 6 days and IGF-1 stayed elevated 9 to 11 days after one dose of the DAC form. With twice-weekly repeat dosing, IGF-1 stayed elevated throughout the multi-week study period without returning to baseline between doses.

What's the difference between CJC-1295 and tesamorelin in terms of trial evidence?

Tesamorelin is a separate GHRH analogue with FDA approval for HIV-associated lipodystrophy, backed by a phase 3 program. CJC-1295 is chemically different, has one phase 1 trial, and has never been reviewed or approved by the FDA for any use.

Does the CJC-1295 trial show fat loss or muscle gain?

No. The 2006 trial measured GH and IGF-1 blood levels and short-term tolerability, not body composition, fat mass, or lean mass. Specific fat-loss or muscle-gain claims associated with CJC-1295 come from forum reports and marketing, not from the published trial.

Who ran the original CJC-1295 clinical trial?

The trial was conducted and published by Teichman and colleagues, sponsored in connection with ConjuChem, the company that developed the DAC (Drug Affinity Complex) technology used in the tested compound, and appeared in the Journal of Clinical Endocrinology & Metabolism in 2006.

Is there long-term safety data on CJC-1295 in humans?

No. The published trial ran over weeks and tracked short-term tolerability, not long-term outcomes over months or years. There is no published data on cancer risk, cardiovascular events, or diabetes onset with extended CJC-1295 use in humans.

Why do people use CJC-1295 twice weekly instead of daily?

The DAC formulation's albumin-binding chemistry gives it a multi-day effective window; the 2006 trial's repeat-dose arm used roughly twice-weekly injections and sustained elevated IGF-1 across the study period, which is the pharmacokinetic basis for that dosing convention.

Are CJC-1295 forum claims backed by clinical data?

Many are not. Specific claims about fat loss percentages, sleep quality, skin effects, or superior combination outcomes with ipamorelin are not measured in the published trial. The trial covers GH/IGF-1 blood levels and short-term tolerability only; the rest is anecdote or marketing extrapolation.

Can I get a prescription for CJC-1295?

It is not an FDA-approved drug, so there's no approved prescribing label. It exists mainly through compounding pharmacies and research-use channels, in a regulatory gray zone. Provider-reviewed, pharmacy-fulfilled sourcing routes exist and are generally safer than unverified direct sales.

Sources

1. Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism (2006): The 2006 phase 1 trial of DAC-CJC-1295 in 80 subjects, its dose-response findings, and GH/IGF-1 elevation duration
2. U.S. Patent and Trademark Office, patent record for GRF analogue conjugates (ConjuChem): DAC (Drug Affinity Complex) albumin-binding chemistry underlying CJC-1295's extended half-life
3. National Library of Medicine, DailyMed archive for sermorelin acetate: Sermorelin's history as an FDA-reviewed GHRH(1-29) analogue, distinct regulatory chain from CJC-1295
4. Raun K, et al., European Journal of Endocrinology (1998), PMID 9849822: Ipamorelin's selective GH-releasing activity via the ghrelin receptor with minimal cortisol/ACTH/prolactin stimulation compared to older GHRPs
5. NIH National Institute of Diabetes and Digestive and Kidney Diseases, Acromegaly overview: Health risks associated with chronic GH/IGF-1 excess, including insulin resistance and cardiovascular effects
6. FDA, Egrifta (tesamorelin) approval and label information: Tesamorelin's FDA approval for HIV-associated lipodystrophy and its distinct phase 3 trial history versus CJC-1295